Scarica l'app Stockscreener
22.97
0.09%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Precedente Chiudi:
$23.02
Aprire:
$22.92
Volume 24 ore:
413.98K
Relative Volume:
0.27
Capitalizzazione di mercato:
$1.75B
Reddito:
-
Utile/perdita netta:
$-130.41M
Rapporto P/E:
-10.25
EPS:
-2.24
Flusso di cassa netto:
$-67.76M
1 W Prestazione:
-2.99%
1M Prestazione:
+39.56%
6M Prestazione:
+285.91%
1 anno Prestazione:
+318.18%
Intervallo 1D:
$22.84
$23.95
Intervallo di 1 settimana:
$22.84
$25.35
Portata 52W:
$3.5001
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Nome
Monte Rosa Therapeutics Inc
Settore
Industria
Telefono
617-949-2643
Indirizzo
321 HARRISON AVENUE, BOSTON
Confronta GLUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
22.98 | 1.76B | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Iniziato | UBS | Buy |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
Mostra tutto
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
51,133 Shares in Monte Rosa Therapeutics, Inc. $GLUE Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Biotech Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 20.7% - MarketBeat
Monte Rosa Therapeutics announces pricing of $300M stock offering - MSN
Goodwin Guides Monte Rosa Therapeutics In Pricing Of $300 Million Underwritten Public Offering - Mondaq
The Bull Case For Monte Rosa Therapeutics (GLUE) Could Change Following MRT-8102 Data And $300 Million Raise - Sahm
Monte Rosa Therapeutics (GLUE) Price Target Increased by 30.77% to 28.49 - Nasdaq
Aug Highlights: Does Monte Rosa Therapeutics Inc stock trade at a discount to peersWeekly Trend Report & High Return Stock Watch Alerts - Bộ Nội Vụ
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum - Yahoo Finance
How institutional buying supports Monte Rosa Therapeutics Inc. stockJuly 2025 Highlights & Daily Market Momentum Tracking - Улправда
Latham & Watkins Advises on Monte Rosa Therapeutics’ US$300 Million Underwritten Public Offering - Latham & Watkins LLP
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares - MarketBeat
Monte Rosa Therapeutics Signs Underwriting Agreement With Jefferies, TD Securities and Piper Sandler - TradingView — Track All Markets
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Monte Rosa Therapeutics Announces Pricing Of $300 Million Underwritten Public Offering At $24.00 Per Share - TradingView — Track All Markets
Monte Rosa Therapeutics Prices Underwritten Public Offering Of $300 Mln Of Shares - Nasdaq
Why Monte Rosa Therapeutics Inc. stock is considered a top pickWeekly Investment Recap & Risk Managed Investment Strategies - ulpravda.ru
Monte Rosa Therapeutics prices $300 million public offering By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Monte Rosa Therapeutics prices $300 million public offering - Investing.com
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - Yahoo Finance
Biotech Monte Rosa is selling $300M in new shares to investors - Stock Titan
Monte Rosa Therapeutics announces pricing of $300 million underwritten public offering at $24.00 per share - marketscreener.com
Can Monte Rosa Therapeutics Inc. stock beat analyst upgradesJuly 2025 Highlights & AI Forecasted Stock Moves - ulpravda.ru
GLUE Stock: Guggenheim Maintains Buy Rating, Raises Price Target - GuruFocus
Will Monte Rosa Therapeutics Inc. stock attract more institutional investorsWeekly Investment Summary & Free AI Powered Buy and Sell Recommendations - Улправда
Is Monte Rosa Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Snapshot & Accurate Buy Signal Notifications - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Why Monte Rosa Therapeutics Inc. stock is a must watch in 2025Weekly Profit Summary & Community Trade Idea Sharing - ulpravda.ru
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
GLUE Stock Receives Analyst Rating Update with Raised Price Targ - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $34.00 Price Target at Guggenheim - MarketBeat
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
Monte Rosa Therapeutics Reaches Analyst Target Price - Nasdaq
Monte Rosa Therapeutics dips after $200 mln equity offering launched - TradingView — Track All Markets
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Strong-Buy - MarketBeat
Monte Rosa Therapeutics launches $200 million public offering By Investing.com - Investing.com Nigeria
Monte Rosa Therapeutics launches $200M public equity offering - MSN
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Investing News Network
Monte Rosa Therapeutics (GLUE) upgraded to strong buy: Here's why - MSN
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets - FinancialContent
Monte Rosa Therapeutics Ends Current ATM Equity Program - TipRanks
Monte Rosa Therapeutics launches $200 million public offering - Investing.com
Monte Rosa Therapeutics (GLUE) Soars on Promising Inflammation Drug Data - RagingBull
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why - sharewise.com
Cardio works out for Monte Rosa in NEK7 phase I - BioWorld MedTech
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush - TipRanks
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighShould You Buy? - MarketBeat
Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):